

Notice of Annual General Meeting

- (iv) **Ordinary Resolution 10:** Authority Pursuant to Section 132D of the Companies Act, 1965 (“Act”) for the Directors to Issue and Allot New Ordinary Shares of RM0.50 each in the Company (“Rights Shares”) pursuant to the Renounceable Rights Issue Approved at the Extraordinary General Meeting of the Company on 11 March 2015 (“EGM”) (“Rights Issue Resolution”).

The shareholders of the Company had, at the EGM held on 11 March 2015 approved the Rights Issue Resolution including the authorization for the Board to provisionally allot and issue by way of a renounceable rights issue of up to 139,479,500 Rights Shares, on the basis of one (1) Rights Share for every one (1) existing ordinary share of RM0.50 each held in the Company, by way of provisional allotment to shareholders whose names appear in the Record of Depositors at the close of business on an entitlement date to be determined and announced later by the Board (“**Entitlement Date**”).

The authority given to the Directors to provisionally allot the Rights Shares in accordance with the Rights Issue Resolution will, pursuant to Section 132D(3)(a) of the Act, lapse at the Annual General Meeting of the Company to be held on 26 May 2015.

As at the date of this Notice, the Proposed Rights Issue has yet to be completed. By virtue of section 132D(3) of the Act, the resolution approved at the EGM shall lapse at the forthcoming AGM and will therefore need to be extended for the purpose of completion of the Proposed Rights Issue.

This mandate for issuance of shares under the Proposed Rights Issue, unless revoked or further varied at a General Meeting, will expire at the conclusion of the next Annual General Meeting of the Company.

Statement Accompanying the Notice of the Fourteenth Annual General Meeting of CCM Duopharma Biotech Berhad

Pursuant to Paragraph 8.27(2), Appendix 8A of the Listing Requirements
of Bursa Malaysia Securities Berhad.

The details of the three (3) Directors of the Company seeking re-election/re-appointment as well as the directors who are proposed to be retained as Independent Directors of the Company are set out in their respective profiles which appear in the Directors’ Profiles on pages 20, 21, 22 and 23 of this Annual Report.

The details of their interest in the securities of the Company are set out in the Analysis of Shareholdings which appear on page 116 of this Annual Report.